Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Brother Enterprises Holding Co.,Ltd. (002562.SZ)
Haining, CN
Brother Enterprises Holding Co.,Ltd. is a diversified Chinese enterprise specializing in the manufacturing and global distribution of chemicals. The company operates through four principal business segments: Leather Chemicals, Vitamins, Flavors and Fragrances, and Active Pharmaceutical Ingredients (APIs). Within its Vitamins division, Brother Enterprises supplies a range of nutritional additives, including vitamin K3, vitamin B1, nicotinamide, niacin, vitamin B5, and alanine. The Leather Chemicals segment provides essential materials for the leather industry, such as chrome tanning agents, retanning agents, fatliquors, and various specialized additives. Under its API portfolio, the company manufactures contrast agent APIs, topiroxostat, and bespoke active pharmaceutical ingredients and intermediates tailored for therapeutic areas such as endocrine and metabolism disorders, nervous system conditions, and respiratory ailments. The Flavors and Fragrances division produces synthetic aromatic compounds like vanillin and ethyl vanillin, alongside other synthetic fragrances. These products find application in the food, daily chemical, and other industrial sectors. This segment also supplies turpentine. Furthermore, Brother Enterprises manufactures molecular sieves and catalysts, as well as several chromium-based compounds, including sodium dichromate, chromic acid, and additional chrome tanning agents. Established in 1991, the company was originally known as Haining Leather Chemicals Factory. Its headquarters are located in Haining, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.89% | -7.18% | -13.99% | -35.38% | -24.10% | -21.98% | +10.53% | +19.43% | +11.26% | -27.55% | +12.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals - Specialty: +4.7%+5.0% ★ Q1'26: +7.4% (vs Q1'25)
-
EPS growth Chemicals - Specialty: +13.2%+125.0% ★ Q1'26: +56.3% (vs Q1'25)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%-3.4% Q1'26: +1.4% (vs Q1'25)
-
EBIT margin Chemicals - Specialty: +8.8%+6.5% Q1'26: +10.1% (vs Q1'25)
-
ROIC Chemicals - Specialty: +5.6%+4.5% Q1'26: +7.2% (vs Q1'25)
-
Share dilution Chemicals - Specialty: +0.1%+3.6% Q1'26: +7.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×1.98× Q1'26: 1.66× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
905.29M
est: 993.00M (-8.8%)
|
1.06B
est: 1.20B (-11.1%)
|
1.56B
est: 1.47B (+6.8%)
|
1.42B
est: 1.59B (-11.3%)
|
1.26B
est: 1.25B (+0.9%)
|
1.92B
est: 2.03B (-5.4%)
|
2.73B
est: 2.55B (+7.4%)
|
3.41B
est: 3.53B (-3.3%)
|
2.82B
est: 4.39B (-35.8%)
|
3.44B
est: 4.73B (-27.3%)
|
| EBITDA |
162.98M
est: 137.88M (+18.2%)
|
269.05M
est: 166.07M (+62.0%)
|
592.57M
est: 203.46M (+191.3%)
|
200.51M
est: 221.43M (-9.4%)
|
202.32M
est: 173.02M (+16.9%)
|
367.74M
est: 281.73M (+30.5%)
|
294.73M
est: 353.38M (-16.6%)
|
694.32M
est: 489.73M (+41.8%)
|
182.53M
est: 609.97M (-70.1%)
|
435.43M
est: 635.38M (-31.5%)
|
| EBIT |
104.01M
est: 30.29M (+243.4%)
|
209.36M
est: 36.48M (+474.0%)
|
479.21M
est: 44.69M (+972.3%)
|
54.63M
est: 48.64M (+12.3%)
|
37.97M
est: 38.00M (-0.1%)
|
119.71M
est: 61.88M (+93.4%)
|
5.65M
est: 77.62M (-92.7%)
|
385.57M
est: 107.57M (+258.4%)
|
-140.04M
est: 133.98M (-204.5%)
|
84.85M
est: 146.56M (-42.1%)
|
| Net Income |
82.24M
est: 130.73M (-37.1%)
|
167.67M
est: 197.69M (-15.2%)
|
403.04M
est: 516.55M (-22.0%)
|
21.82M
est: 40.81M (-46.5%)
|
43.83M
est: 51.02M (-14.1%)
|
28.03M
est: 132.64M (-78.9%)
|
28.33M
est: 214.27M (-86.8%)
|
305.55M
est: 326.51M (-6.4%)
|
-175.47M
est: 550.98M (-131.8%)
|
40.81M
est: 676.31M (-94.0%)
|
| SGA |
103.61M
est: 84.38M (+22.8%)
|
182.46M
est: 101.63M (+79.5%)
|
172.26M
est: 124.51M (+38.4%)
|
172.63M
est: 135.50M (+27.4%)
|
240.49M
est: 105.88M (+127.1%)
|
251.06M
est: 172.41M (+45.6%)
|
211.43M
est: 216.25M (-2.2%)
|
243.47M
est: 299.69M (-18.8%)
|
218.59M
est: 373.28M (-41.4%)
|
233.32M
est: 343.43M (-32.1%)
|
| EPS |
0.12
est: 0.13 (-7.3%)
|
0.20
est: 0.19 (+3.2%)
|
0.47
est: 0.51 (-7.2%)
|
0.03
est: 0.04 (-25.0%)
|
0.05
est: 0.05 (+0.0%)
|
0.03
est: 0.13 (-76.9%)
|
0.03
est: 0.21 (-85.7%)
|
0.29
est: 0.32 (-10.3%)
|
-0.17
est: 0.54 (-131.5%)
|
0.04
est: 0.64 (-93.8%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-28 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-27 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-26 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-25 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-22 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-21 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-20 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-19 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-18 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-15 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-14 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-13 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-12 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-11 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-08 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-07 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-06 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | B- | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | B- | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | B- | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | B- | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | B- | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | B- | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | B- | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | B- | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | B- | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | B- | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 119.1K | 0.39% |
| 2 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 75.3K | 0.29% |
| 3 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 31.6K | 0.28% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hui Chen | Deputy General Manager | — | male |
| Jianping Li | President & Director | — | male |
| Liu Hua Qian | Board Secretary | — | female |
| Qingquan Liu | Vice President & Director | — | female |
| Wei Ming Lin | Accounting Supervisor | — | — |
| Yonghui Zhang | Vice President & Financial Director | — | male |
| Zhongping Zhou | Vice President & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 002562.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
